Quality meltdown still affects J&J financials, though Q3 sales are up

Johnson & Johnson ($JNJ) reports today in third-quarter financials that U.S. sales of OTC medicines were "significantly impacted" by the shutdown of McNeil's Consumer Healthcare manufacturing plant in Fort Washington, PA, the main player in its many Tylenol recalls over the last two years. In addition, ongoing remediation work lowered production volumes. Nonetheless, overall sales were up nearly 7% over last year's Q3. Release

Suggested Articles

Eli Lilly is investing $400 million in its Indianapolis site to expand production of insulin and other diabetes meds, and add 100 jobs.

Recipharm has been building its capabilities in sterile injectable and inhalation drugs. Now it is buying a CDMO that manufactures devices for both.

The FDA has slapped the parent of Dollar Tree stores with a warning letter saying some CMOs that made its OTC products were among the world's worst.